The team at MassDevice.com and Drug Delivery Business News will be updating this post periodically as news comes out of ACC 2017, the annual American College of Cardiology meeting in Washington March 17-19. Boston Scientific touts 3-year outcomes for Synergy bioabsorbable drug-eluting stent Data presented at ACC 2017 showed that Boston Scientific‘s (NYSE:BSX) Synergy bioabsorbable polymer drug-eluting […]
Cardiovascular
Medtech stories we missed this week: March 3, 2017
Several clinical study results were published this week, while other companies reached distribution deals. Here are some medtech stories we missed this week but were still worth mentioning. 1. Health Canada approves Ventripoint’s complete heart analysis system for 2D ultrasounds Ventripoint Diagnostics received a license from Health Canada for its new VMS-Plus machine and the 4-chamber (4C) heart […]
Research shows stem cell treatment could improve irregular heartbeat
A study published in Stem Cells Translational Medicine showed that treating heart patients with mesenchymal stem cells does not increase their risk for irregular heart beat and instead improved the patients’ cardiac conditions. Previous studies have shown that stem cells have the potential to repair the damage caused by heart disease, but there was speculation that some […]
Blood test could accurately diagnose heart disease
A simple blood test could accurately diagnose heart disease in 2 hours, according to new data published by life science company Prevencio. Prevencio researchers and the Massachusetts General Hospital collaborated to develop a clinical and multi-protein blood test that could diagnose obstructions in coronary arteries, leading to the prevention of a heart attack. The blood test, known as […]
This 3D heart tissue beats—and is made from multiple cardiac cell types
Scientists at Toronto’s York University have created 3D heart tissue that has a synchronized beat. They think the tissue could improve understanding of cardiac health as researchers develop new treatments. Muhammad Yousaf, a York University chemistry professor, and his graduate student team stuck three types of cardiac cells together to get a 3D heart tissue that beats […]
BioCardia, Johns Hopkins treats first patient with CardiAmp cell therapy in Phase III trial
Johns Hopkins, the Maryland Stem Cell Research Fund and BioCardia (NSDQ:BCDA) said today that the 1st patient has been treated in a pivotal Phase III trial of the CardiAmp cell-based therapy for the treatment of ischemic heart failure. The investigational therapy was designed to deliver a dose of a patient’s own bone marrow cells directly […]
Amgen wins marketing authorization for Repatha single-dose delivery option
Amgen (NSDQ:AMGN) said today that the European Commission granted a change to the marketing authorization of its Repatha device, approving a single-dose delivery option. The pre-filled cartridge mini-doser is a hands-free device that is designed to provide 420 mg of Repatha (evolocumab) in a single injection for patients with cardiovascular disease. The company touted its […]
Amgen tops Q4 earnings, touts Repatha cardiovascular outcomes
Shares in Amgen (NSDQ:AMGN) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results and touted data from a trial for its cholesterol drug, Repatha. The Thousand Oaks, Calif.-based company posted profits of $1.94 billion, or $2.59 per share, on sales of $5.97 billion for the 3 months ended Dec. 31, for bottom-line […]
J&J, Actelion still in talks despite Opsumit failure
Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ). The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart […]
BioCardia launches pivotal trial for CardiAmp heart failure treatment
BioCardia (NSDQ:BCDA) initiated its CardiAmp pivotal trial this week to evaluate its cell therapy at 40 clinical sites across the U.S. The pivotal trial is a part of the company’s efforts for premarket approval, as regulated by the FDA’s Center for Biologics Evaluation and Research division. “We are honored to be working with the leading […]
